Wei Li

Wei Li

Auto-generated profile, based on publicly available information

Wei Li

Royal Brompton Hospital

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in International Journal of Cardiology
Verified
Journal Article
Open access
WLWei Li
Wei Li
CWCathy West
Cathy West
JMJackie McGhie
Jackie McGhie
ABAnnemien E. van Den Bosch
Annemien E. van Den Bosch
SBSonya V. Babu-Narayan
Sonya V. Babu-Narayan
GWGary Webb
Gary Webb
The population of adults with congenital heart disease (ACHD) is increasing constantly due to medical, surgical and interventional successes and the input from advanced cardiovascular imaging. ACHD patients are at continuing risk of residua and sequelae related to their CHD contributing to significant morbidity and mortality. Consequently, lifelong expert surveillance is recommended for most patients. Healthcare providers are still working out how best to achieve this objective, how to train enough experts to provide high quality care, and how to organize the delivery of care. Echocardiography is crucial to clinical surveillance providing a comprehensive assessment of cardiac morphology, physiology, pathophysiology, and function. Thus it contributes significantly to the overall clinical management of ACHD patients. The International Society for Adult Congenital Heart Disease (ISACHD; www.isachd.org) is the leading organization of professionals worldwide dedicated to the pursuit of excellence in the care of ACHD patients. Recognizing the critical role of imaging in the diagnosis and management of ACHD, ISACHD established a task force to provide guidance on echocardiographic studies and reporting. The rationale is that standardization of echocardiographic imaging and reporting carries the potential to improve the overall quality of these exams around the world and facilitate collaborative multicenter research. The standardized ACHD protocols provided by the ISACHD task force (found in the appendices) include specific recommendations for data acquisition and reporting for each of the major adult congenital heart lesions. These protocols give a comprehensive and structured approach in the evaluation of ACHD patients and help to ensure excellent patient care.

29 September 2022 in Respirology
Verified
Journal Article
Open access
TDTimothy J. W. Dawes
Timothy J. W. Dawes
CMColm McCabe
Colm McCabe
KDKonstantinos Dimopoulos
Konstantinos Dimopoulos
ISIain Stewart
Iain Stewart
SBSimon Bax
Simon Bax
LPLaura C. Price
Laura C. Price
Background and Objective: Pulmonary hypertension is a life‐limiting complication of interstitial lung disease (ILD‐PH). We investigated whether treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with ILD‐PH was associated with improved survival.Methods: Consecutive incident patients with ILD‐PH and right heart catheterisation, echocardiography and spirometry data were followed from diagnosis to death, transplantation or censoring with all follow‐up and survival data modelled by Bayesian methods.Results: The diagnoses in 128 patients were idiopathic pulmonary fibrosis (n = 74, 58%), hypersensitivity pneumonitis (n = 17, 13%), non‐specific interstitial pneumonia (n = 12, 9%), undifferentiated ILD (n = 8, 6%) and other lung diseases (n = 17, 13%). Final outcomes were death (n = 106, 83%), transplantation (n = 9, 7%) and censoring (n = 13, 10%). Patients treated with PDE5i (n = 50, 39%) had higher mean pulmonary artery pressure (median 38 mm Hg [interquartile range, IQR: 34, 43] vs. 35 mm Hg [IQR: 31, 38], p = 0.07) and percentage predicted forced vital capacity (FVC; median 57% [IQR: 51, 73] vs. 52% [IQR: 45, 66], p=0.08) though differences did not reach significance. Patients treated with PDE5i survived longer than untreated patients (median 2.18 years [95% CI: 1.43, 3.04] vs. 0.94 years [0.69, 1.51], p = 0.003) independent of all other prognostic markers by Bayesian joint‐modelling (HR 0.39, 95% CI: 0.23, 0.59, p < 0.001) and propensity‐matched analyses (HR 0.38, 95% CI: 0.22, 0.58, p < 0.001). Survival difference with treatment was significantly larger if right ventricular function was normal, rather than abnormal, at presentation (+2.55 years, 95% CI: −0.03, +3.97 vs. +0.98 years, 95% CI: +0.47, +2.00, p = 0.04).Conclusion: PDE5i treatment in ILD‐PH should be investigated by a prospective randomized trial.

6 May 2021 in Heart
Verified
Journal Article
Closed access
PDF file
MLMagalie Ladouceur
Magalie Ladouceur
TCTeresa Segura de la Cal
Teresa Segura de la Cal
BGBamba Gaye
Bamba Gaye
EVEugenie Valentin
Eugenie Valentin
RLReaksmei Ly
Reaksmei Ly
KDKonstantinos Dimopoulos
Konstantinos Dimopoulos
Background To date, clinical trials have been underpowered to demonstrate a benefit from ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) in preventing systemic right ventricle (sRV) failure and disease progression in patients with transposition of the great arteries (TGA). This observational study aimed to estimate the effect of ACEi and ARB on heart failure (HF) incidence and mortality in a large population of patients with an sRV. Methods Data on all patients with an sRV under active follow-up at two tertiary centres between January 2007 and September 2018 were studied. The effect of ACEi and ARB on the incidence of HF and mortality was estimated using a propensity score weighting approach to control confounding. Results Among the 359 patients with an sRV (32.2 (IQR 26.4–38.3) years, 59.3% male, 66% complete TGA with atrial switch repair and 34% congenitally corrected TGA), 79 (22%) had a moderate to severe sRV dysfunction and 138 (38%) were treated with ACEi or ARB. Fourteen (3.6%) patients died, 8 (2.1%) underwent heart transplantation and 46 (11.8%) had a new HF event over a median follow-up of 7.1 (IQR 4.0–9.4) years. On multivariate Cox analysis with adjustment using propensity score weighting approaches, ACEi or ARBs treatment was not significantly associated with a lower HF incidence or mortality in patients with an sRV. Conclusions Despite significant neurohormonal activation described in patients with an sRV, there is still no evidence of a beneficial effect of ACEi or ARB on morbidity and mortality in this population.

5 November 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
YYYanrong Yin
Yanrong Yin
KDKonstantinos Dimopoulos
Konstantinos Dimopoulos
ESEriko Shimada
Eriko Shimada
KLKaren Lascelles
Karen Lascelles
SGSamuel Griffiths
Samuel Griffiths
WLWei Li
Wei Li
Background: There are limited data about cardiac resynchronization therapy ( CRT ) in adult congenital heart disease. We aimed to assess early and late outcomes of CRT among patients with adult congenital heart disease. Methods and Results: We retrospectively studied 54 patients with adult congenital heart disease (median age, 46 years; range, 18–73 years; 74% men) who received CRT implantation (biventricular paced >90%) between 2004 and 2017. Clinical and echocardiographic data were analyzed at baseline and early (mean±SD: 1.8±0.8 years) and late (4.7±0.8 years) follow‐up after CRT . Compared with baseline, CRT was associated with significant improvement at early follow‐up in New York Heart Association functional class, QRS duration, and cardiothoracic ratio ( P <0.05 for all); improvement in New York Heart Association class was sustained at late follow‐up. Among patients with a systemic left ventricle ( LV ; n=39), there was significant increase in LV ejection fraction and reduction in LV end‐systolic volume at early and late follow‐up ( P <0.05 for both). For patients with a systemic right ventricle (n=15), there was a significant early but not late reduction in systemic right ventricular basal and longitudinal diameters. Eleven patients died, and 2 had heart transplantation unrelated to systemic ventricular morphological characteristics. Thirty‐five patients (65%) responded positively to CRT , but only baseline QRS duration was predictive of a positive response. Conclusions: CRT results in sustained improvement in functional class, systemic LV size, and function. Patients with a systemic LV and prolonged QRS duration, independent of QRS morphological characteristics, were most likely to respond to CRT .

1 January 2011 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
SCSylvia Sm Chen
Sylvia Sm Chen
JKJennifer Keegan
Jennifer Keegan
ADAndrew William Dowsey
Andrew William Dowsey
TITevfik Ismail
Tevfik Ismail
RWRicardo Wage
Ricardo Wage
PKPhilip J Kilner
Philip J Kilner
Right ventricular ejection fraction (RV-EF) has traditionally been used to measure and compare RV function serially over time, but may be a relatively insensitive marker of change in RV myocardial contractile function. We developed a cardiovascular magnetic resonance (CMR) tagging-based technique with a view to rapid and reproducible measurement of RV long axis function and applied it in patients with congenital heart disease.

30 April 2022 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
Alexandra ArvanitakiAlexandra Arvanitaki
Alexandra Arvanitaki
WIWasyla Ibrahim
Wasyla Ibrahim
DSDarryl Shore
Darryl Shore
GDGerhard-Paul Diller
Gerhard-Paul Diller
WLWei Li
Wei Li
CMClaudia Montanaro
Claudia Montanaro